GMABHealthcare · Biotechnology
Genmab A/S
DeepValues Research covers Genmab A/S (GMAB) with 1 research report since Jul 5, 2026. The latest Deep Value Intelligence report (Jul 5, 2026) ends with a Bearish stance (4.01/5). Sector: Healthcare · Biotechnology.
Research timeline
-
Deep Value Intelligence
Genmab A/S (GMAB) Deep Value Intelligence ReportBearish (4.01/5) on Genmab A/S (GMAB), Jul 5, 2026. Price $29. GMAB's deterministic dataset shows a business with unusually strong economics for a…
Compare with other Healthcare companies
All Healthcare stocks| Company | Latest stance | Reports |
|---|---|---|
| GMABGenmab A/S | Bearish4.01 | 1 |
| ALLOAllogene Therapeutics | Bearish3.10 | 1 |
| MRNA | Neutral3.01 | 1 |
| CRSPCRISPR Therapeutics | Neutral2.30 | 1 |
| INSMInsmed | Bearish2.52 | 1 |
| MNKDMannKind | Neutral2.63 | 1 |
| TPSTTempest Therapeutics | Bearish2.65 | 1 |
| ADMAADMA Biologics | Neutral3.37 | 1 |
| LENZLENZ Therapeutics | Bearish3.12 | 1 |
Charts from the latest report
Open report
